DaVita HealthCare Partners Inc. (NYSE:DVA) was downgraded by investment analysts at TheStreet from a “b” rating to a “c+” rating in a report issued on Wednesday, August 2nd.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Jefferies Group LLC reissued a “hold” rating and set a $70.00 target price on shares of DaVita HealthCare Partners in a report on Thursday, August 3rd. BidaskClub cut shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Finally, Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $62.00 target price on shares of DaVita HealthCare Partners in a report on Thursday, May 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $68.89.
Shares of DaVita HealthCare Partners (DVA) traded up 0.11% on Wednesday, reaching $56.98. 1,243,308 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 52 week low of $54.50 and a 52 week high of $70.16. The stock has a market capitalization of $10.89 billion, a PE ratio of 8.68 and a beta of 0.89. The company has a 50 day moving average of $62.45 and a 200-day moving average of $65.58.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.02. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.82 billion. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. Equities research analysts forecast that DaVita HealthCare Partners will post $3.57 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. raised its position in DaVita HealthCare Partners by 6.6% in the first quarter. SRS Capital Advisors Inc. now owns 1,966 shares of the company’s stock valued at $133,000 after buying an additional 122 shares in the last quarter. Raymond James Trust N.A. purchased a new position in DaVita HealthCare Partners during the first quarter valued at approximately $202,000. Advisor Partners LLC purchased a new position in DaVita HealthCare Partners during the first quarter valued at approximately $218,000. Wetherby Asset Management Inc. raised its position in DaVita HealthCare Partners by 3.3% in the first quarter. Wetherby Asset Management Inc. now owns 3,224 shares of the company’s stock valued at $219,000 after buying an additional 104 shares in the last quarter. Finally, Pzena Investment Management LLC raised its position in DaVita HealthCare Partners by 2.1% in the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after buying an additional 71 shares in the last quarter. Institutional investors and hedge funds own 83.53% of the company’s stock.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
